Functional Promoter -308G>A Variant in Tumor Necrosis Factor α Gene Is Associated with Risk and Progression of Gastric Cancer in a Chinese Population

Yan Hong1*, Zhijun Ge1*, Changrui Jing2, Jun Shi1, Xiao Dong3, Fengying Zhou4, Meilin Wang5, Zhengdong Zhang5, Weida Gong1,3,6*

1 Department of Surgery, Yixing People’s Hospital, Yixing, China, 2 Department of Plastic Surgery, Wuxi No.2 People’s Hospital, Wuxi, China, 3 Department of Surgery, Yixing Cancer Hospital, Yixing, China, 4 Department of Breast Surgery, Wuxi Maternal and Child Health Hospital, Wuxi, China, 5 Department of Molecular and Genetic Toxicology, School of Public Health, Nanjing Medical University, Nanjing, China, 6 Cancer Center, Nanjing Medical University, Nanjing, China

Abstract

Background: Tumor necrosis factor-α (TNF-α) plays a crucial role in the development and progression of gastric cancer. A functional polymorphism, -308 G>A (rs1800629), which is located in the promoter of TNFA gene, has been suggested to alter the production of TNF-α and influence cancer risk. In the present study, we sought to investigate whether this polymorphism has effects on the risk and progression of gastric cancer in a Chinese population.

Methods: We genotyped the TNFA -308 G>A polymorphism using the TaqMan method in a two-stage case-control study comprising a total of 1686 gastric cancer patients and 1895 cancer-free subjects. The logistic regression was used to assess the genetic associations with occurrence and progression of gastric cancer.

Results: We found a significant association between the variant genotypes and increased risk of gastric cancer (P = 0.034, odds ratio (OR) = 1.39, 95% confidence interval (CI) = 1.01–1.67, GA/AA vs. GG). Similar results were observed in the follow-up replication study. When combined the data from the two studies, we found a more significant association (P = 0.001, OR = 1.34, 95% CI = 1.13–1.59), especially for older subjects (>65 years). Furthermore, the patients carrying the variant genotypes had a significantly greater prevalence of T4 stage of disease (P = 0.001, OR = 2.19, 95% CI = 1.39–3.47) and distant metastasis (P = 0.013, OR = 1.61, 95% CI = 1.10–2.35).

Conclusions: Our results suggest that the functional promoter -308 G>A polymorphism in TNFA influence the susceptibility and progression of gastric cancer in the Chinese population.

Introduction

Gastric cancer is the fourth most common cancer and the second leading cause of cancer-related death worldwide, and particularly prevalent in certain countries, including China [1,2]. Although the exact etiology of gastric cancer remains to be identified, accumulating epidemiological studies have shown that diet, smoking, alcohol and especially Helicobacter pylori (H. pylori) infection, are well-known causes of gastric cancer [3,4]. However, a high prevalence of these risk factors do not always result in a high incidence of gastric cancer, which suggests that other susceptible factors such as genetic variations and environmental differences may additionally contribute to gastric carcinogenesis. Recently, emerging evidence has suggested that genetic polymorphisms in candidate genes were associated with susceptibility to gastric cancer [5,6,7].

It has been suggested that chronic inflammation in gastric mucosa induced by the H. pylori infection is a critical step in the development of gastric cancer [8,9]. In that case, genetic variations in inflammation-related cytokine genes may be potential susceptibility factors for this disease. One of the important cytokines associated with H. pylori infection is the tumor necrosis factor (TNF) –α which is encoded by the TNFA gene [10]. TNF-α is a pleiotropic cytokine mainly produced by activated monocytes and macrophages and plays an important role in the inflammatory response [11]. It has been suggested that over expression of TNF-α showed a significant severity-dose-response as risk markers from pre-neoplastic lesions to gastric cancer [12].

The TNFA gene is located within the human leukocyte antigen class III region on chromosome 6 (6p21) and is highly polymorphic. Polymorphisms in the TNFA gene have been shown
to greatly influence its expression level [13]. Therefore, many studies attempted to investigate whether polymorphisms in the promoter of TNFA could be used as putative determinant factor of susceptibility for various diseases, including gastric cancer. Among the many polymorphisms in TNFA promoter, the TNFA-308 G>A polymorphism were widely studied and there is functional study suggesting that the -308A allele is associated with increased TNF-α production [14]. As for gastric cancer, a number of studies were conducted to investigate the associations between the TNFA-308 G>A polymorphism and gastric cancer in various populations, however, the results from these studies remain inclusive [15,16,17,18,19]. To date, two published meta-analyses on this issue have suggested that the -308 G>A polymorphism was associated with gastric cancer in Western populations, but not in Asian populations [20,21]. Herein, in the present study, we conducted a relative large two-stage case-control study that included a total of 1686 gastric cancer patients and 1895 cancer-free subjects to further evaluate the influence of the TNFA -308 G>A polymorphism on gastric cancer risk and progression in a Chinese population.

Materials and Methods

Ethics statement

The study was approved by the Institutional Review Board of the Nanjing Medical University, Nanjing, China. At recruitment, written informed consent was obtained from all participants involved in this study.

Study population

This is an ongoing molecular epidemiologic study of gastric cancer conducted in the First Affiliated Hospital of Nanjing Medical University, Nanjing, China. The design of the study and the inclusion criteria of the subjects were previously described elsewhere [22]. In brief, two independent hospital-based case-control studies were included in the present study. Overall, the test set included 750 gastric cases and 835 age and sex-matched controls recruited at the second affiliated hospital of Nanjing Medical University, Nanjing and Cancer Hospital of Nantong City, Nantong, China from March, 2006 to January, 2010, and the validation set included 936 cases and 1,060 controls enrolled from Yixing People’s Hospital, Yixing, China from January, 1999 to December, 2006. All subjects were ethnic Han Chinese coming from different families and had no blood relationship. All the patients were newly diagnosed with histopathologically confirmed, incident gastric cancer and were consecutively recruited without restriction of age and sex. Histological sections of all cases were reviewed by two pathologists independently. Those patients that had previous cancer, metastasized cancer from other or unknown origin, or previous radiotherapy or chemotherapy were excluded. The controls were recruited from healthy subjects who were seeking physical examination in the outpatient departments at the corresponding hospital and were frequency-matched to the cases by age (±5 years) and sex. The cancer-free controls were genetically unrelated to the cases and had no individual history of cancer. Each patient donated 5 ml venous blood after providing a written informed consent. The response rate for case and control subjects was both above 85%.

DNA extraction and genotyping

The whole genomic DNA was isolated and purified from leucocytes of peripheral blood by protease K digestion and phenol/chloroform extraction. The TNFA -308 G>A polymorphism was genotyped using the TaqMan-MGB method (Applied Biosystems, Foster City, CA, USA), which uses two allele-specific TaqMan MGB probes and a PCR primer pair to detect the specific SNP target. The sequence of the primers and probes are available on request. The reaction mixture of 10 μL contained 20 ng genomic DNA, 3.5 μL of 2× TaqMan Genotyping Master Mix, 0.25 μL of the primers and probes mix and 6.25 μL of double distilled water. The amplification was performed under the following conditions: 95°C for 2 min, 95°C for 10 min followed by 45 cycles of 95°C for 15 sec, and 60°C for 1 min. Following the manufacturer’s instructions, amplifications were conducted in the 384-well ABI 7900HT Real Time PCR System (Applied Biosystems, Foster City, CA, USA) and the allelic discrimination were performed using the SDS 2.4 software (Applied Biosystems, Foster City, CA, USA). The genotyping rates of these SNPs were all above 90%. To ensure the accuracy of genotyping, two negative experimental control (water) and two positive experimental controls with known genotype were included in each reaction plate. In addition, about 5% of the samples were randomly selected for repeated genotyping for confirmation; and the results were 100% concordant.

Statistical analysis

Before further analysis, the allele frequencies of TNFA -308G>A polymorphism in the controls of test set, validation set and combined set were assessed against departure from Hardy-Weinberg equilibrium (HWE) using a goodness-of-fit χ²-test. Differences in the distributions of age, sex and frequencies of genotypes of the TNFA -308G>A polymorphism between the cases and controls were evaluated by Pearson’s χ² test. The associations between the -308G>A genotypes and risk of gastric cancer as well as the clinical characteristics of the patients were measured by computing odds ratios (ORs) and 95% confidence intervals (CIs) from unconditional logistic regression analysis with the adjustment for age and sex. All the statistical analyses were performed with the software SAS 9.1.3 (SAS Institute, Cary, NC, USA) and a two-side P value of less than 0.05 was considered as statistically significant.

Results

Characteristics of the study population

The frequency distributions of demographic characteristics and clinical features of the two sets of study group are shown in Table 1. The cases and controls were matched by age and sex (P=0.393 and 0.424 in the test set and P=0.164 and 0.061 in the validation set, respectively). Although more older subjects (>65 years) and female subjects were presented in the test set than in the validation set, no significant difference in age and sex between the cases and controls was observed when we combined the two populations (Table 1). In the test set, there were 295 cardia gastric cancer (CGC) patients and 453 non-cardia gastric cancer (NCGC) patients; 406 patients diagnosed as diffuse type of gastric cancer and 299 as intestinal type. Clinical TNM stage is categorized according to depth of invasion, lymph node metastasis and distant metastasis. The percent of TNM stage of patients in the test set from I to IV were 26.6%, 22.0%, 35.3%, and 15.7%, respectively. Of the 936 patients in the validation set, 358 were CGC and 578 were NCGC; 339 patients diagnosed as diffuse type of gastric cancer and 397 as intestinal type. Approximately 27.7%, 19.8%, 42.2% and 10.3% of the patients were found to have TNM stage I, II, III and IV diseases, respectively.
Association between the TNFA -308 G>A polymorphism and gastric cancer risk

The genotyping results of the TNFA -308 G>A polymorphism among the patients and controls in the two study set are presented in Table 2. The observed genotype frequencies in the controls of test set, validation set and the combined set were all conformed to the HWE (P = 0.481, 0.448 and 0.946, respectively). We then used Pearson’s χ² test and logistic regression analysis to assess the association between TNFA -308 G>A polymorphism and gastric cancer risk. In the test set, we found that there were more variant genotypes (GA/AA) in the case group than that in the control group (P = 0.034). Compared with the individuals with GG genotype, we found those subjects with GA/AA genotypes had an increased risk of gastric cancer (adjusted OR = 1.39, 95%CI = 1.01–1.67). Similar associations were observed in the replication study (GA vs. GG: OR = 1.29, 95%CI = 1.02–1.65 and GA/AA vs. GG: OR = 1.31, 95%CI = 1.03–1.65). When we combined data from the two studies, a more significant association was observed (GA vs. GG: OR = 1.33, 95%CI = 1.12–1.59 and GA/AA vs. GG: OR = 1.34, 95%CI = 1.13–1.59).

To evaluate if the TNFA -308 G>A polymorphism plays different role in subgroups of age, sex, tumor site and histological types, we then performed stratified analysis based on these variables. As shown in Table 3, the stratified analysis showed that the increased risk associated with the TNFA -308GG/GA genotypes was more evident among older subjects (> 65 years) (P < 0.001, OR = 1.70, 95%CI = 1.28–2.25). Besides, no significant difference was observed in the stratification of sex, tumor site and histological types.

Association between the TNFA -308 G>A polymorphism and clinical characteristics of the patients with gastric cancer

Polymorphisms in candidate genes have been suggested to influence cancer progression. We then evaluated whether the TNFA -308 G>A polymorphism has effects on the clinical characteristics of the patients, including TNM stage, distant metastasis, lymph node metastasis and depth of tumor infiltration. As shown in Table 4, we found that the patients carrying the variant genotypes had a significantly greater prevalence of T4
stage of invaded depth ($P = 0.001$, OR = 2.19, 95%CI = 1.39–3.47) and distant metastasis ($P = 0.013$, OR = 1.61, 95%CI = 1.10–2.35), indicating the polymorphism might be associated with gastric cancer progression.

**Discussion**

The main findings of our study are the significant associations between the TNFA -308 G>A polymorphism and gastric cancer risk and progression. TNF-α is an important immune mediator in inflammatory response and has been suggested to be an endogenous tumor promoter in human carcinogenesis.

### Table 2. Genotype and allele frequencies of TNF-α -308 G>A polymorphism among the cases and controls and their associations with risk of gastric cancer.

| Genotypes | Cases, N (%) | Controls, N (%) | $P^*$ | OR (95% CI)* | Adjusted OR (95% CI)† |
|-----------|--------------|-----------------|------|--------------|----------------------|
| The test set | | | | | |
| GG | 589 (78.5) | 690 (82.7) | 0.098 | 1.00 (reference) | 1.00 (reference) |
| GA | 154 (20.6) | 139 (16.7) | 1.30 (1.01–1.67) | 1.29 (1.00–1.66) |
| AA | 7 (0.9) | 5 (0.6) | 1.64 (0.52–5.19) | 1.59 (0.50–5.06) |
| GA+AA | 161 (21.5) | 144 (17.3) | 0.034 | 1.31 (1.02–1.68) | 1.39 (1.01–1.67) |
| A allele | 168 (11.2) | 149 (8.9) | 0.034 | 1.29 (1.02–1.62) | - |
| The validation set | 1332 | 1519 | | | |
| GG | 746 (79.7) | 895 (84.4) | 0.022 | 1.00 (reference) | 1.00 (reference) |
| GA | 179 (19.1) | 156 (14.7) | 1.37 (1.09–1.74) | 1.29 (1.02–1.65) |
| AA | 11 (1.2) | 9 (0.9) | 1.46 (0.60–3.55) | 1.44 (0.59–3.54) |
| GA+AA | 190 (20.3) | 165 (15.6) | 0.002 | 1.38 (1.10–1.74) | 1.31 (1.03–1.65) |
| A allele | 201 (10.7) | 174 (0.2) | 0.006 | 1.35 (1.09–1.54) | - |
| Combined | 1671 | 1946 | | | |
| GG | 1335 (79.2) | 1585 (83.7) | 0.002 | 1.00 (reference) | 1.00 (reference) |
| GA | 333 (19.8) | 295 (15.6) | 1.34 (1.13–1.59) | 1.33 (1.12–1.59) |
| AA | 18 (1.1) | 14 (0.7) | 1.52 (0.76–3.08) | 1.54 (0.76–3.14) |
| GA+AA | 351 (20.8) | 309 (16.3) | 0.001 | 1.35 (1.14–1.60) | 1.34 (1.13–1.59) |
| A allele | 369 (10.9) | 323 (8.5) | 0.001 | 1.32 (1.13–1.54) | - |

*Two-sided $\chi^2$ test 3003 3465.
† Were adjusted for age and sex. OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0050856.t002

### Table 3. Stratification analyses between TNFA -308 G>A polymorphism and gastric cancer risk in the combined group.

| Variables | TNFA -308 G>A genotypes | | Adjusted OR (95% CI)† |
|-----------|--------------------------|-----------------|----------------------|
| | GG (N, %) | GA/AA (N, %) | $P^*$ | | |
| | Cases | Controls | Cases | Controls | |
| Age (years) | | | | | |
| ≤65 | 820 (79.5) | 962 (82.4) | 211 (20.5) | 206 (17.6) | 0.091 | 1.17 (0.95–1.45) |
| >65 | 515 (78.6) | 623 (85.8) | 140 (21.4) | 103 (14.2) | <0.001 | 1.70 (1.28–2.25) |
| Sex | | | | | |
| Male | 970 (78.8) | 1095 (82.4) | 261 (21.2) | 234 (17.6) | 0.021 | 1.27 (1.04–1.55) |
| Female | 365 (80.2) | 490 (86.7) | 90 (19.8) | 75 (13.3) | 0.005 | 1.63 (1.15–2.32) |
| Site | | | | | |
| Cardia | 517 (79.2) | 1585 (83.7) | 136 (21.8) | 309 (16.3) | 0.009 | 1.34 (1.07–1.68) |
| Non-cardia | 818 (79.2) | 1585 (83.7) | 215 (21.8) | 309 (16.3) | 0.002 | 1.35 (1.12–1.64) |
| Histological types | | | | | |
| Diffuse | 753 (79.7) | 1585 (83.7) | 192 (20.3) | 309 (16.3) | 0.008 | 1.32 (1.08–1.61) |
| Intestinal | 551 (29.2) | 1585 (83.7) | 145 (20.8) | 309 (16.3) | 0.007 | 1.34 (1.08–1.67) |

*Two-sided $\chi^2$ test.
† Were adjusted for age, sex. OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0050856.t003
In gastric cancer, Senthilkumar et al. demonstrated that TNF-α mRNA and protein expressions were significantly increased in gastric adenocarcinoma patients, by using RT-PCR, western blotting and immunohistochemistry [12]. The influence of the -308G>A polymorphism on the expression level of TNE4 has been previously investigated. Karen et al. showed that the -308G>A polymorphism could affect the affinity of factor binding and result in a factor binding to the -308A allele but not the -308G allele, which then lead to an increased expression of TNE4 [14]. Considering that TNF-α is up-regulated in gastric cancer, it is possible that individuals carrying the -308A allele (ie. GA/AA), which is associated with increased level of TNF-α, have an increased risk for gastric cancer. Therefore, it is biologically plausible that the TNE4 -308G>A confers individuals’ susceptibility to gastric cancer.

To date, several molecular epidemiological studies have been conducted to investigate the association between the TNE4 -308G>A polymorphism and gastric cancer risk. However, the results from these studies remain inconclusive. There are two published meta-analyses on the associations between the TNE4 -308G>A and gastric cancer risk that have identified this polymorphism as a risk factor for gastric cancer in Caucasian populations but not in Asian populations [20,21]. When reviewed the two meta-analyses, we found only 3 studies with a total of 513 cases and 714 controls and 5 studies with a total of 833 cases and 1375 controls in Chinese populations were included in the meta-analyses of Zhang et al. [20] and Gorouhi et al. [21], respectively (Table 5). The number of studies and the sample size of these studies may be too limited to generate a stable result. Of these studies, only Lu et al. found a significant association between TNE4 -308GA genotype and increased risk of gastric cancer risk (OR = 1.81, 95%CI = 1.04–3.14). Our study further identify the TNE4 -308G>A polymorphism as a risk factor for gastric cancer in Chinese population, which may be of value in evaluating the role of TNF-α in gastric carcinogenesis. As indicated by Power and Sample Size Calculation software, our study had a 96% power to detect an OR of 1.50 or greater and a minimal OR of 0.62 with an exposure frequency of 9% at the current sample size (1686 cases and 1895 controls), which suggests that the sample size of our study is efficient.

In addition, we found that the TNE4 -308G>A polymorphism was associated with increased risk of gastric cancer among subgroups of older subjects (age >65 years) rather than younger subjects. This observation is well supported by a large body of studies, which link weak immune system with ageing [26,27]. The immune system of aged individuals undergoes alterations that may account for an increased susceptibility to malignancies [26]. It has been proposed that high expression of TNF-α might be involved in tumor growth and spread through influencing tissue remodeling and stromal development [28,29]. In our study, we also found the

### Table 4. The association between TNE4 -308 G>A polymorphism and the progression of gastric cancer.

| Category                      | GG (N, %) | GA/AA (N, %) | P* | Adjusted OR (95% CI)* |
|-------------------------------|-----------|--------------|----|-----------------------|
| Depth of invasion             |           |              |    |                       |
| T1                            | 216 (80.9)| 51 (19.1)    | 1.00 (reference) |
| T2                            | 253 (79.3)| 66 (20.7)    | 0.654 | 1.10 (0.73–1.65) |
| T3                            | 726 (81.3)| 167 (18.1)   | 0.861 | 0.97 (0.68–1.37) |
| T4                            | 96 (65.8) | 50 (34.3)    | 0.001 | 2.19 (1.39–3.47) |
| Lymph node metastasis         |           |              |    |                       |
| Positive                      | 549 (78.0)| 155 (22.0)   | 1.00 (reference) |
| Negative                      | 786 (80.0)| 196 (20.0)   | 0.305 | 0.88 (0.70–1.12) |
| Distant metastasis            |           |              |    |                       |
| M0                            | 1199 (80.3)| 295 (19.8)  | 1.00 (reference) |
| M1                            | 106 (71.6)| 42 (28.4)    | 0.013 | 1.61 (1.10–2.35) |
| TNM stage                     |           |              |    |                       |
| I                             | 355 (79.2)| 93 (20.8)    | 1.00 (reference) |
| II                            | 268 (78.8)| 72 (21.2)    | 0.915 | 1.02 (0.72–1.44) |
| III                           | 530 (82.2)| 115 (17.8)   | 0.220 | 0.83 (0.61–1.12) |
| IV                            | 151 (72.6)| 57 (27.4)    | 0.061 | 1.44 (0.98–2.11) |

* were adjusted for age and sex in logistic regression model. CI: confidence interval; OR: odds ratio.

doi:10.1371/journal.pone.0050856.t004

### Table 5. Comparison of the sample size of the studies conducted in Chinese populations.

| Studies          | Meta-analysis 1* | Meta-analysis 2† | Our study |
|------------------|------------------|------------------|-----------|
|                  | Case Control     | Case Control     | Case Control |
| Li et al. [15]   | 59 264           | 59 264           | - -         |
| Lu et al. [16]   | 250 300          | 250 300          | - -         |
| Wu et al. [17]   | 204 210          | 204 210          | - -         |
| Fei et al. [18]  | 56 164           | - -              | - -         |
| Guo et al. [19]  | 264 437          | - -              | 1686 1895   |
| Our study        | - -              | - -              | 1686 1895   |
| Total            | 833 1375         | 513 714          | 1686 1895   |

*The meta-analysis of Gorouhi et al [21].
†The meta-analysis of Zhang et al [20].
doi:10.1371/journal.pone.0050856.t005
TNFA -308G>A polymorphism was associated with clinical aggressiveness such as advanced tumor stage and distant metastasis. Similar observation has also been reported in other study [30]. If confirmed by additional studies, this polymorphism might help to accurately predict the clinical course of gastric cancer. However, these results should be interpreted with cautious because there is possibility that the associations with poor prognosis are due to a late stage at diagnosis.

When interpreting our results, some other limitations should also be concerned. First, since our study was hospital-based design, the possibility of selection bias of subjects that were associated with a particular genotype might exist. However, the genotype distributions in our controls were similar to distributions reported in other Chinese studies and conformed to HWE. Therefore, the selection bias in terms of genotype distributions would not be substantial. Second, H. pylori infection status is a well-known cause of gastric cancer and has been suggested to influence the expression of TNF-α [31]. Genetic variations in TNFA may interact with this factor to affect gastric cancer risk. Unfortunately, lack of available information on H. pylori infection status in our study limited us to further explore these interactions. Thus, further studies with more detailed data on H. pylori infection are warranted.

In conclusion, our results suggest the -308G>A polymorphism in the promoter of TNFA has a significant influence on the occurrence and progression of gastric in the Chinese population. Although the associations appeared to be statistically significant in our population, these findings should be independently verified by other prospective studies with larger sample size simultaneous of well-matched controls and unbiased-matched homogeneous participants.

Author Contributions

Conceived and designed the experiments: WG ZZ ZG. Performed the experiments: YH FZ. Analyzed the data: YH FZ WG ZG JS. Contributed reagents/materials/analysis tools: YH XD CJ. Wrote the paper: YH FZ WG ZG MW.

References

1. Parkin DM, Bray F, Ferlay J, Pisani P (2003) Global cancer statistics 2002. CA Cancer J Clin 53: 74–108.
2. Hohenberger P, Bretschel S (2003) Gastric cancer. Lancet 362: 305–315.
3. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, et al. (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784–789.
4. Crew KD, Neugut AI (2004) Epidemiology of upper gastrointestinal malignancies. Semin Oncol 31: 450–464.
5. Yoshida T, Ono H, Kuchiba A, Saeki N, Sakamoto H (2010) Genome-wide germline analysis on cancer susceptibility and GeMDB database: Gastric cancer as an example. Cancer Sci 101: 1582–1589.
6. Wang M, Zhang R, He J, Luo Q, Li J, et al. (2011) Potential variants of PLCE1 identified by GWAS contribute to gastric adenocarcinoma susceptibility in an eastern Chinese population. PLoS One 7: e31932.
7. Shi Y, Hu Z, Wu C, Dai J, Li H, et al. (2011) A genome-wide association study identifies new susceptibility loci for non-cardia gastric cancer at 3p13.31 and 5p13.1. Nat Genet 43: 1215–1218.
8. You NC, Zhang L, Guo MH, Chang YS, Liu WD, et al. (2000) Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors. J Natl Cancer Inst 92: 1607–1612.
9. Pook RM Jr, Blaser MJ (2002) Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2: 28–37.
10. Yeas SS, Yang YL, Jiang WH, Lee YJ, Bae HS, et al. (2001) Association between TNF-alpha promoter polymorphism and Helicobacter pylori cagA subtype infection. J Clin Pathol 54: 703–706.
11. Thalmaier U, Lohr P, Pfeiffer K, Stölte M, Vieth M, et al. (2002) Role of tumor necrosis factor receptor 1-deficient mice. Infect Immun 70: 3149–3155.
12. Senthilkumar C, Niranjali S, Jayanthi V, Ramesh T, Devaraj H (2011) Molecular and histological evaluation of tumor necrosis factor-alpha expression in Helicobacter pylori-mediated gastric carcinogenesis. J Cancer Res Clin Oncol 137: 577–585.
13. Raabe T, Bukinsky M, Currie RA (1999) Relative contribution of transcription and translation to the induction of tumor necrosis factor-alpha by lipopolysaccharide. J Biol Chem 273: 974–980.
14. Kroeger KM, Carville KS, Abraham LJ (1997) The -308 tumor necrosis factor-alpha promoter polymorphisms effects transcription. Mol Immunol 34: 391–399.
15. Li C, Xia B, Yang Y, Li J, Xia HH (2005) TNF gene polymorphisms and Helicobacter Pylori infection in gastric carcinogenesis in Chinese population. Am J Gastroenterol 100: 290–294.
16. Lu W, Pan K, Zhang L, Lin D, Xiao X, et al. (2003) Genetic polymorphisms of interleukin (IL)-1β, IL-1RN, IL-8, IL-10 and tumor necrosis factor α [alpha] and risk of gastric cancer in a Chinese population. Carcinogenesis 26: 631–636.
17. Wu MS, Huang SP, Chang YT, Shun CT, Chang MC, et al. (2002) Tumor necrosis factor-alpha and interleukin-10 promoter polymorphisms in Epstein-Barr virus-associated gastric carcinoma. J Infect Dis 185: 106–109.